Teacher Retirement System of Texas Makes New $330,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Teacher Retirement System of Texas acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,905 shares of the company's stock, valued at approximately $330,000.

A number of other institutional investors have also made changes to their positions in the business. NBC Securities Inc. acquired a new position in shares of TransMedics Group in the first quarter valued at $25,000. Atlas Capital Advisors Inc. acquired a new position in shares of TransMedics Group in the fourth quarter valued at about $31,000. AlphaQuest LLC acquired a new position in shares of TransMedics Group in the fourth quarter valued at about $52,000. Sava Infond d.o.o. acquired a new position in shares of TransMedics Group in the fourth quarter valued at about $94,000. Finally, GAMMA Investing LLC grew its stake in shares of TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock valued at $105,000 after acquiring an additional 1,324 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Insiders Place Their Bets

In other news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider directly owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Weill sold 732 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the sale, the director directly owned 12,134 shares in the company, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,418 shares of company stock worth $1,512,613. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Price Performance

TMDX traded up $1.99 during midday trading on Tuesday, hitting $105.60. The stock had a trading volume of 1,822,028 shares, compared to its average volume of 1,392,074. The company has a market cap of $3.57 billion, a P/E ratio of 77.65 and a beta of 2.06. The business has a fifty day moving average of $127.13 and a 200 day moving average of $92.64. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The business's revenue was up 48.2% on a year-over-year basis. During the same quarter last year, the business earned $0.35 earnings per share. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TMDX has been the subject of a number of research reports. Oppenheimer increased their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Piper Sandler reissued an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Canaccord Genuity Group increased their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $129.88.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.